Our top pick for
Passage Bio Inc is a biotechnology business based in the US. Passage Bio shares (PASG) are listed on the NASDAQ and all prices are listed in US Dollars. Passage Bio employs 74 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$9.17|
|52-week range||$9.10 - $30.14|
|50-day moving average||$10.63|
|200-day moving average||$13.39|
|Wall St. target price||$28.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-3.15|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-14)||-9.12%|
|1 month (2021-09-21)||-17.54%|
|3 months (2021-07-21)||-29.79%|
|6 months (2021-04-21)||-46.96%|
|1 year (2020-10-21)||-48.10%|
|2 years (2019-10-17)||N/A|
|3 years (2018-10-17)||N/A|
|5 years (2016-10-17)||N/A|
|Gross profit TTM||$0|
|Return on assets TTM||-22.41%|
|Return on equity TTM||-40.43%|
|Market capitalisation||$527.4 million|
TTM: trailing 12 months
There are currently 2.9 million Passage Bio shares held short by investors – that's known as Passage Bio's "short interest". This figure is 16.3% down from 3.5 million last month.
There are a few different ways that this level of interest in shorting Passage Bio shares can be evaluated.
Passage Bio's "short interest ratio" (SIR) is the quantity of Passage Bio shares currently shorted divided by the average quantity of Passage Bio shares traded daily (recently around 295636.01220753). Passage Bio's SIR currently stands at 9.83. In other words for every 100,000 Passage Bio shares traded daily on the market, roughly 9830 shares are currently held short.
However Passage Bio's short interest can also be evaluated against the total number of Passage Bio shares, or, against the total number of tradable Passage Bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Passage Bio's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Passage Bio shares in existence, roughly 50 shares are currently held short) or 0.0934% of the tradable shares (for every 100,000 tradable Passage Bio shares, roughly 93 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Passage Bio.
Find out more about how you can short Passage Bio stock.
We're not expecting Passage Bio to pay a dividend over the next 12 months.
Passage Bio, Inc. , a genetic medicines company, develops transformative therapies for rare monogenic central nervous system (CNS) diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase (ß-gal) for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin, or GRN, gene encoding progranulin, or PGRN, for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A, as well as programs for the treatment of adult CNS indication. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. .
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.